Received 15 December 2015; accepted 8 March 2016; published 11 March 2016
Alzheimer’s disease, the devastating neurodegenerative disease occurring at epidemic proportions (1 in 85 people) is predicted to reach ~115.4 million people in 2050  . Despite screening 1000 s of drugs to treat AD   , any worthwhile drug is yet to come. Rather, many drugs, immunization with Aβ  for its clearance and Aβ generating gamma and beta-secretase inhibitors hardly showed any protection in clinical trials. So a potential treatment for AD is an urgent necessity.
Antihypertensive drugs provide protection against Dementia. A screen of many antihypertensive drugs to reduce Aβ aggregates in a cell culture model led to the identification of Valsaratan which was later proved to provide protection in AD model mice  , which is currently in clinical trials  . The Cache County study suggests that patients taking antihypertensive drugs are less likely to develop Alzheimer’s disease  .
Reserpine is a FDA approved antihypertensive drug from the roots of Rauwolfia serpentina, known as Sarpaganda being used in ayurvedic medicine in India for 1000s of years  to treat insanity, snake bites and as a tranquilizer. Independently, we identified that reserpine could provide high quality lifespan extension in C. elegans  . In addition, reserpine ameliorates Aβ-induced toxicity manifested as progressive paralysis, confered stress tolerance and enhanced locomotion till late age in the C. elegans model  . The AD mouse model, Tg2576, expresses human mutant APP, which causes Aβ aggregates formation and cognitive deficits at ~11 months of age  . In these Tg2576 mice, reserpine reduced Aβ 42 deposits and levels in hippocampus and serum  . But reserpine’s effect on the major problem of AD, namely, cognitive deficit―progressive dementia or memory loss was not addressed.
Here, we address whether reserpine: 1) provides protection against Aβ toxicity induced cognitive deficits in the 5XFAD AD Tg model and 2) improves cognition in normal mice.
2. Materials and Methods
2.1. Animals and Maintenance
The mice were maintained in standard animal house facility with ad libitum access to food and water. All animal protocols were approved by the Institutional Animal Ethics Committee and in accordance with the guidelines of CPCSEA. The 5X FAD AD Tg mice  (obtained from Jackson laboratory, Ann Arbor, USA) were bred with wild-type non-transgenic mice to yield transgenic and non-transgenic littermates and genotyped using the standard tail DNA genomic PCR with relevant primer sets sets (APP: APP-FP (AGGACTGACCACTCGACCAG) & APP-RP (CGGGGGTCTAGTTCTGCAT); Presenilin1: PS1-FP (AATAGAGAACGGCAGGAGCA) & PS1 -RP (GCCATGAGGGCACTAATCAT)).
2.2. Reserpine Treatment
Reserpine (Sigma) (0.08 mg), dissolved in fruit vinegar and diluted with dextrose-saline was orally administered to human mapp+m psen1+(5XFAD)/non-transgenic mice on alternate days from 2 months of age till 5 months. This dosage and duration was arrived at based on the specific concentration at which reserpine had protective effects in C. elegans   and the prescription used for hypertension  . For control, the vehicle, fruit vinegar, diluted with saline dextrose was administered. All the mice were age and sex matched. The treatment was done as three independent sets, with 4 or 5 mice per group with approximately equal number of males and females.
2.3. Behavioral Analyses
After one month of drug regimen, spatial working memory was tested with minor modifications  . This learning task assesses hippocampus dependent spatial learning, working memory and exploratory activity. Mice were individually placed in the center of the symmetrical Y-maze consisting of three arms separated by 120 degrees (arm size: 40 cm long; 13 cm high and 10 cm wide). Mice were allowed to explore freely through the Y- maze during a 5 min session. The sequence of arms entered and total number of arms entered were recorded. Number of arm entry was considered when all the four paws were placed inside the arm. This behavior was evaluated on alternate days starting from 3 months up to 5 months of age, since the 5XFAD Tg mice shows poor performance of spontaneous alternation from the age of ~4 months due to cognitive decline as described previously  . The number of triads was calculated as 3 sequential entries into three different arms (i.e. 1, 2, 3 or 2, 3, 1).
2.4. Statistical Analysis
The data obtained was analyzed using SigmaPlot version 10.0 and the statistical significance was performed by student’s t test. All results were expressed as mean ± standard deviation. P-value < 0.01 and P-value < 0.001 were considered to be statistically significant.
Reserpine, an antihypertensive drug was protective in the Aβ toxicity model in C. elegans. Further, reserpine reduced Aβ levels in the Tg2576 AD model mice. Here, we evaluated the crux of the disease, improvement from the cognitive deficit impairment, measured using the behavioral paradigm-spontaneous alteration in the Y maze for working memory in the 5XFAD AD Tg mouse model. They develop cerebral Aβ plagues (aggregates) rapidly at two months of age and show memory impairment in Y maze by 4 months of age. Both APP and PS1 segregate together  and the mice with these genes were identified.
3.1. Reserpine Delays Cognitive Deficits in the 5XFAD AD Tg Mice
In order to determine reserpine’s ability to alleviate Aβ toxicity in the mouse model, in which the actual behavioral deficit in cognition could be determined, we orally administered the 5XFAD AD Tg mice with ~0.08 mg of reserpine on alternate days from two months of age up to 5 months of age. We followed the improvement in the cognitive paradigm, spontaneous alteration behavior task in the Y-maze on alternate days, usually on the next day after reserpine oral administration. The behavioral paradigm evaluation was started after one month of initiation of drug regimen and monitored for 2 months which is up to 5 months of age.
In the Y-maze paradigm, overall total movement and spontaneous arm alteration counted as triad (entry into all the three arms in a sequential manner) were measured in the 5X FAD AD Tg mice. Each trial lasted for 5 minutes. Reserpine increases the overall movement and the maximum activity is observed after one month of initiation of behavioral paradigm. The actual measure of cognitive enhancement/protection measured as increase in the number of triads entered also peaks after 20 days of start of the Y-maze behavioral paradigm. Of these, ~8 days (118 - 126 days of age) (Figure 1) showed the maximum protection which was statistically significant (P < 0.005/P < 0.05).
3.2. Reserpine Treatment Enhances Cognition in the Normal Mice
When normal non-Tg mice were treated with the same dose of reserpine as the human mutant app+psen1+ mice they showed improvement in cognition as number of triads entered (Figure 2). Moreover, the enhancement was statistically significant (**―P < 0.005 and *―P < 0.05) for a long duration of almost one month (Figure 2). Thus, reserpine was able to enhance normal cognition as well.
The 5XFAD AD Tg mouse model showed enhanced spatial working memory measured by increase in the number of triads entered when they were chronically administered with low dosage (0.08 mg) reserpine orally on alternate days for a period of three months. More importantly, reserpine improved the cognition of the 5xFAD AD Tg mice at the age (Figure 1) where these mice are reported to show cognitive deficits. While our study was ongoing, Go et al.  reported that reserpine can help relieve AD pathogenesis in Tg2576 mice through down
Figure 1. Reserpine increasing cognition in the 5XFAD AD Tg mice. Number of triads entered by V-Vehicle (n = 14) and R-reserpine treated (n = 14) 5XFAD Tg mice at different ages. V-Vehicle; R-Reserpine treated; **―P < 0.001; *―P < 0.01. Error bar-Standard Deviation.
Figure 2. Reserpine improves cognitive ability in the non-Tg mice. The no. of triads entered by V-Vehicle (n = 14) and R-reserpine treated (n = 14) non-Tg mice at different ages. **―P < 0.001; *―P < 0.01. Error bar-Standard Deviation.
regulation of Aβ42 deposition, NGF secretion  , but had not assessed cognitive function. Since decline in cognition is the most devastating feature of AD, here, we show that reserpine improves spatial working memory and delays cognitive deficits in the 5XFAD AD Tg mice at the low dosage of 0.08 mg that too administered only on alternate days which is in line with the low dosage of reserpine currently in use. Reserpine is effective as an antihypertensive drug at as low a dosage as 0.05 mg   . In addition, reserpine enhances cognition in the normal mice (Figure 2). This suggests that reserpine can be considered for detailed evaluation in the 3X Tg (human mutant APP, mutant Presenilin 1 and mutant tau) AD mouse model and a pilot screen in AD patients.
In addition to dementia, due to the progressive neuronal loss, other complications like anxiety, paranoia, aggression, hallucinations, delusions, and depression and sleep disturbances make management of AD patients extremely difficult. As reserpine modulates biogenic amines neurotransmitters, the secondary problems mentioned above also could be alleviated by it. Go et al.  , report that reserpine can significantly reduce the aggressive behavior in the Tg2576 AD mice. In Ayurvedic medicine, reserpine has been used as an antipsychotic and tranquilizer for more than a millennium.
Reserpine has a strong potential to be a candidate drug for AD, because: 1) first and foremost, it improves working memory (Figure 1 and Figure 2); 2) it decreases Aβ 42-deposits/levels in brain and serum  ; 3) it increases NGF secretion and its action through TrkA signaling  ; 4) it induces expression of antiapoptotic protein, BCL-2 which can protect against neuronal loss  ; 5) it does not inhibit or drastically downregulate the gamma-secretase complex  which is crucial for notch signaling, lack of which leads to cancer   ; 6) it can cross the blood brain barrier; 7) the major caveat about reserpine is the development of depression, and at a low dosage of 1 mg/kg reserpine does not cause depression in mice and the maniac depression pathological marker mkb-1 is not induced  , but at the dosage of 2 mg/kg both these effects are noticed  ; 8) it is widely in use, especially as an antihypertensive drug, even as a community based prophylactic at the low dosage of 0.05 mg against hypertension with minimal side effects for several years   ; 9) it reduces mortality when used as an antihypertensive  .
Thus, Reserpine ameliorates Aβ induced cognitive deficit in the 5XFAD Tg mice at a low dosage of 0.08 mg orally administered on alternate days. Hence, reserpine’s efficacy can be evaluated in detail in the 3xTG AD model mice. In addition, reserpine analogs could be synthesized and evaluated for protection against AD. More importantly, given the limitations of animal models, exceptionally fruitful approach will be to carry out a pilot screen in AD patients given the severity, prevalence, social and financial burden on the society and the urgent need of a drug for AD.
Reserpine ameliorates Aβ induced cognitive deficit in the 5XFAD Tg mice at a low dosage of 0.08 mg orally administered on alternate days. This makes reserpine a potential drug to be evaluated in AD patients. As reserpine is originally identified to be protective in the Aβ toxicity C. elegans model, the C. elegans system is a worthwhile model for preclinical drug discovery.
The authors acknowledge the financial support from Department of Biotechnology, Government of India and Jackson laboratory, Ann Arbor USA for the 5xFAD AD Tg mice.
 Mori, T., Koyama, N., Segawa, T., Maeda, M., Maruyama, N., Kinoshita, N., Hou, H., Tan, J. and Town, T. (2014) Methylene Blue Modulates β-Secretase, Reverses Cerebral Amyloidosis, and Improves Cognition in Transgenic Mice. Journal of Biological Chemistry, 289, 30303-30317.
 Wollen, K.A. (2010) Alzheimer’s Disease: The Pros and Cons of Pharmaceutical, Nutritional, Botanical, and Stimulatory Therapies, with a Discussion of Treatment Strategies from the Perspective of Patients and Practitioners. Alternative Medicine Review, 15, 223-244.
 Savonenko, A.V., Melnikova, T., Hiatt, A., Li, T., Worley, P.F., Troncoso, J.C., Wong, P.C. and Price, D.L. (2012) Alzheimer’s Therapeutics: Translation of Preclinical Science to Clinical Drug Development. Neuropsychopharmacology, 37, 261-277.
 Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P.S., Siemers, E., Liu-Seifert, H., Mohs, R., Alzheimer’s Disease Cooperative Study Steering Committee and Solanezumab Study Group (2014) Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease. The New England Journal of Medicine, 370, 311-321.
 Glenner, G.G. and Wong, C. (1984) Alzheimer’s disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein. Biochemical and Biophysical Research Communications, 120, 885-890.
 Song, M.S., Rauw, G., Baker, G.B. and Kar, S. (2008) Memantine Protects Rat Cortical Cultured Neurons against Beta-Amyloid-Induced Toxicity by Attenuating Tau Phosphorylation. European Journal of Neuroscience, 28, 1989-2002.
 Borchelt, D.R., Ratovitski, T., van Lare, J., Lee, M.K., Gonzales, V., Jenkins, N.A., Copeland, N.G., Price, D.L. and Sisodia, S. (1997) Accelerated Amyloid Deposition in the Brains of Transgenic mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins. Neuron, 19, 939-945.
 Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R. and Vassar, R. (2006) Intraneuronal Beta-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer’s Disease Mutations: Potential Factors in Amyloid Plaque Fomation. The Journal of Neuroscience, 26, 10129-10140.
 Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., Humala, N., Seror, I., Bartholomew, S., Rosendorff, C. and Pasinetti, G. (2007) Valsartan Lowers Brain Beta-Amyloid Protein Levels and Improves Spatial Learning in a Mouse Model of Alzheimer Disease. Journal of Clinical Investigation. 117, 3393-3402.
 Khachaturian, A.S., Zandi, P.P., Lyketsos, C.G., Hayden, K.M., Skoog, I., Norton, M.C., Tschanz, J.T., Mayer, L.S., Welsh-Bohmer, K.A. and Breitner, J.C. (2006) Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study. Archives of Neurology, 63, 686-692.
 Lele, R. (2010) Beyond Reverse Pharmacology: Mechanism-Based Screening of Ayurvedic Drugs. Journal of Ayurveda and Integrative Medicine, 1, 257-265.
 Srivastava, D., Arya, U., SoundaraRajan, T., Dwivedi, H., Kumar, S. and Subramaniam, J.R. (2008) Reserpine Can Confer Stress Tolerance and Lifespan Extension in the Nematode C. elegans. Biogerontology, 9, 309-316.
 Arya, U., Dwivedi, H. and Subramaniam, J.R. (2009) Reserpine Ameliorates Aβ Toxicity in the Alzheimer’s Disease Model in Caenorhabditis elegans. Experimental Gerontology, 44, 462-466.
 Go, J., Cho, S.I., Kim. J.I, Lee, Y.J., Kwak, M.H., Koh, E.K., Song, S.H., Sung, J.E. and Hwang, D.Y. (2013) Effect of Reserpine on the Behavioral Defects, Aβ-42 Deposition and NGF Metabolism in Tg2576 Transgenic Mouse Model for Alzheimer’s Disease. Journal of Life Sciences, 23, 812-824.
 Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W.L., Vassar, R. and Disterhoft, J.F. (2006) Temporal Memory Deficits in Alzheimer’s Mouse Models: Rescue by Genetic Deletion of BACE1. European Journal of Neuroscience, 23, 251-260.
 Curb, J.D., Schneider, K., Taylor, J.O., Maxwell, M. and Shulman, N. (1988) Antihypertensive Drug Side Effects in the Hypertension Detection and Follow-Up Program. Hypertension, 11, 1151-1155.
 Lee, H.R., Hwang, I.S., Kim, J.E., Cho, S.I., Lee, Y.J., Goo, J.S., Lee, E.P., Choi, H.W., Kim, H.S., Lee, J.H., Jung, Y.J. and Hwang, D.Y. (2012) Altered Expression of γ-Secretase Components in Animal Model of Major Depressive Disorder Induced by Reserpine Administration. Laboratory Animal Research, 28, 109-114.